Inclusion Criteria:  The diagnosis of ICC Patients must have at least one tumor lesion that can be accurately measured according to mRECIST criteria. Stand first-line chemotherapy resistance. Performance status (PS) ≤ 2 (ECOG scale). Child Pugh score ≤ 7. Not amendable to surgical resection ,local ablative therapy and any other cured treatment. Platelet count ≥ 50,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥ 32 g/L ASL and AST ≤ 6 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) >1,500/mm3 Sign the written informed consent, and be able to follow the visit and relevant procedures specified in the plan  Exclusion Criteria:  Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy Known history of HIV History of organ allograft Known or suspected allergy to the investigational agents or any agent given in association with this trial. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy Evidence of bleeding diathesis. Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. Known central nervous system tumors including metastatic brain disease Tumor burden≥70%, diffuse liver cancer or tumor is not suitable for mRECIST standard evaluation. Received local treatment (ablation therapy), surgery resection and radiotherapy for ICC before the first administration. Tumor thrombus of main portal vein, or involving superior mesenteric vein at the same time.